Pasithea Therapeutics Corp Stock Price Patterns

KTTA Stock  USD 0.80  0.06  6.47%   
The RSI of Pasithea Therapeutics' share price is below 30 at this time. This indicates that the stock is becoming oversold or undervalued. The main point of the Relative Strength Index (RSI) is to track how fast people are buying or selling Pasithea Therapeutics Corp, making its price go up or down.

Momentum 22

 Sell Stretched

 
Oversold
 
Overbought
The successful prediction of Pasithea Therapeutics' future price could yield a significant profit. We analyze noise-free headlines and recent hype associated with Pasithea Therapeutics Corp, which may create opportunities for some arbitrage if properly timed. Below are the key fundamental drivers impacting Pasithea Therapeutics' stock price prediction:
Wall Street Target Price
3
Quarterly Revenue Growth
14.981
Using Pasithea Therapeutics hype-based prediction, you can estimate the value of Pasithea Therapeutics Corp from the perspective of Pasithea Therapeutics response to recently generated media hype and the effects of current headlines on its competitors.
The fear of missing out, i.e., FOMO, can cause potential investors in Pasithea Therapeutics to buy its stock at a price that has no basis in reality. In that case, they are not buying Pasithea because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.

Pasithea Therapeutics after-hype prediction price

    
  USD 0.83  
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Check out Pasithea Therapeutics Basic Forecasting Models to cross-verify your projections.
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Pasithea Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Intrinsic
Valuation
LowRealHigh
0.071.376.19
Details
Naive
Forecast
LowNextHigh
0.020.865.68
Details
1 Analysts
Consensus
LowTargetHigh
2.733.003.33
Details

Pasithea Therapeutics After-Hype Price Density Analysis

As far as predicting the price of Pasithea Therapeutics at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Pasithea Therapeutics or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Pasithea Therapeutics, with the unreliable approximations that try to describe financial returns.
   Next price density   
       Expected price to next headline  

Pasithea Therapeutics Estimiated After-Hype Price Volatility

In the context of predicting Pasithea Therapeutics' stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Pasithea Therapeutics' historical news coverage. Pasithea Therapeutics' after-hype downside and upside margins for the prediction period are 0.04 and 5.65, respectively. We have considered Pasithea Therapeutics' daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models compare with traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
0.80
0.83
After-hype Price
5.65
Upside
Pasithea Therapeutics is dangerous at this time. Analysis and calculation of next after-hype price of Pasithea Therapeutics is based on 3 months time horizon.

Pasithea Therapeutics Stock Price Outlook Analysis

Have you ever been surprised when a price of a Company such as Pasithea Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Pasithea Therapeutics backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Pasithea Therapeutics, there might be something going there, and it might present an excellent short sale opportunity.
Expected ReturnPeriod VolatilityHype ElasticityRelated ElasticityNews DensityRelated DensityExpected Hype
  0.44 
4.07
  0.01 
  0.05 
7 Events / Month
3 Events / Month
In about 7 days
Latest traded priceExpected after-news pricePotential return on next major newsAverage after-hype volatility
0.80
0.83
2.35 
13,567  
Notes

Pasithea Therapeutics Hype Timeline

Pasithea Therapeutics is now traded for 0.80. The entity has historical hype elasticity of -0.01, and average elasticity to hype of competition of -0.05. Pasithea is anticipated to decline in value after the next headline, with the price expected to drop to 0.83. The average volatility of media hype impact on the company price is over 100%. The price decrease on the next news is expected to be -2.35%, whereas the daily expected return is now at -0.44%. The volatility of related hype on Pasithea Therapeutics is about 3815.63%, with the expected price after the next announcement by competition of 0.75. About 23.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 0.39. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Pasithea Therapeutics recorded a loss per share of 4.43. The entity had not issued any dividends in recent years. The firm had 1:20 split on the 2nd of January 2024. Given the investment horizon of 90 days the next anticipated press release will be in about 7 days.
Check out Pasithea Therapeutics Basic Forecasting Models to cross-verify your projections.

Pasithea Therapeutics Related Hype Analysis

Having access to credible news sources related to Pasithea Therapeutics' direct competition is more important than ever and may enhance your ability to predict Pasithea Therapeutics' future price movements. Getting to know how Pasithea Therapeutics' peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Pasithea Therapeutics may potentially react to the hype associated with one of its peers.

Pasithea Therapeutics Additional Predictive Modules

Most predictive techniques to examine Pasithea price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Pasithea using various technical indicators. When you analyze Pasithea charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.

About Pasithea Therapeutics Predictive Indicators

The successful prediction of Pasithea Therapeutics stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Pasithea Therapeutics Corp, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Pasithea Therapeutics based on analysis of Pasithea Therapeutics hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Pasithea Therapeutics's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Pasithea Therapeutics's related companies.
 2023 2024 2025 (projected)
PB Ratio0.40.230.27
Capex To Depreciation0.05293.0E-64.0E-6

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Complementary Tools for Pasithea Stock analysis

When running Pasithea Therapeutics' price analysis, check to measure Pasithea Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pasithea Therapeutics is operating at the current time. Most of Pasithea Therapeutics' value examination focuses on studying past and present price action to predict the probability of Pasithea Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pasithea Therapeutics' price. Additionally, you may evaluate how the addition of Pasithea Therapeutics to your portfolios can decrease your overall portfolio volatility.
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Commodity Directory
Find actively traded commodities issued by global exchanges
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets